Compare Amphastar Pharmaceuticals Inc (AMPH) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Emerson Electric Co. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Emerson Electric Co. trades at $137.56 (market cap $77.79B). The key difference: Emerson Electric Co. is far larger — about 94.2× Amphastar Pharmaceuticals Inc's market cap, and Emerson Electric Co. pays a 1.6% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EMR | |
|---|---|---|
Market Cap | $826.08M | $77.79B |
Sector | Health | Industrials |
52-Week High | $30.81 | $161.69 |
52-Week Low | $16.87 | $123.30 |
Enterprise Value | $1.22B | $90.05B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Emerson Electric (EMR) trades at $138.88, up 0.78% today, with a bearish technical signal from moving averages. The stock shows stable revenue growth, with 2025 revenue of $18.02B and net income of $2.29B, supported by a strong gross profit margin of 52.67%. Recent news highlights investor attention and collaboration with Aramco on corrosion R&D, while the Intelligent Devices segment gains momentum.
EMR presents a mixed outlook: analyst consensus is bullish with a $157.60 price target, but technical indicators suggest near-term pressure. Key risks include volatile cash flows and competitive pressures in manufacturing electronics. The stock's valuation at a P/E of 32.15 may limit upside unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
